Translating Socioenvironmental Influences on Neurocognitive Development and Addiction Risk (TranSINDA) (U01 Clinical Trial Not Allowed)
ID: 355495Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/355495

Additional Information

http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-037.html
Timeline
    Description

    The National Institutes of Health (NIH) is inviting applications for the funding opportunity titled "Translating Socioenvironmental Influences on Neurocognitive Development and Addiction Risk (TranSINDA)," which aims to support cooperative research agreements. The initiative seeks to conduct longitudinal studies utilizing animal models to investigate how early-life socioenvironmental factors influence neurocognitive development and the risk of substance use disorders (SUD). This program is significant for advancing understanding of the neurobiological mechanisms linking socioenvironmental influences to addiction vulnerabilities, potentially informing new prevention and intervention strategies. The NIH plans to allocate $4 million to fund up to seven awards over a maximum project period of five years, with applications due by November 8, 2024. Interested applicants can find more information and submission guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    RFA-DA-25-037-Full-Announcement.html
    RFA-DA-25-037.html
    The National Institutes of Health (NIH) is seeking applications for cooperative research agreements under the funding opportunity titled "Translating Socioenvironmental Influences on Neurocognitive Development and Addiction Risk (TranSINDA)." The goal is to conduct longitudinal studies using animal models to explore how early-life socioenvironmental factors impact neurocognitive development and the risk of substance use disorders (SUD). This initiative emphasizes innovative team-science research supported by advanced neuroscience tools. Key dates include an application due date of November 8, 2024, with an anticipated start date of November 7, 2024. The program plans to allocate $4 million to potentially fund up to seven awards over a maximum project period of five years. Applications must include a Plan for Enhancing Diverse Perspectives (PEDP) to showcase efforts in fostering inclusivity within research activities. The document specifies eligible organizations, application submission guidelines, and review criteria emphasizing the importance of research significance, investigator qualifications, innovation, and thorough methodological approaches. The TranSINDA program aims to address critical gaps in understanding the neurobiological mechanisms linking socioenvironmental factors to addiction vulnerabilities, potentially leading to new strategies for prevention and intervention in substance abuse.
    Similar Opportunities
    Translating Socioenvironmental Influences on Neurocognitive Development and Addiction Risk (TranSINDA) (U24 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through its National Institute on Drug Abuse (NIDA), has announced a funding opportunity for a Data Coordination Center (DCC) as part of the Translating Socioenvironmental Influences on Neurocognitive Development and Addiction Risk (TranSINDA) initiative. The DCC will be responsible for managing and sharing data within the TranSINDA Consortium, establishing a modern data ecosystem that promotes open science and collaboration in data standards and management protocols, while also providing statistical and modeling support for research on early-life factors influencing addiction risk. This initiative is critical for enhancing data accessibility and fostering inclusivity in the research workforce, with a funding commitment of $1 million for one award over a maximum project period of five years. Interested applicants must submit their proposals by December 3, 2024, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment (R61/R33 Basic Experimental Studies with Humans Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment," aimed at encouraging clinical research to explore novel non-invasive brain stimulation (NIBS) targets for treating substance use disorders (SUD). This initiative seeks applications for exploratory and developmental studies that will identify and validate neurobiological, cognitive, and behavioral responses to NIBS, with the goal of understanding mechanisms that could lead to reduced cravings and substance use. The NIH plans to allocate $1.5 million in funding for fiscal years 2024-2026, with an award ceiling of $500,000 per project phase, and key submission dates starting December 16, 2023. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment (R01 Basic Experimental Studies with Humans Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment (R01 Basic Experimental Studies with Humans Required)," aimed at advancing research on non-invasive brain stimulation (NIBS) as a treatment for substance use disorders (SUDs). This initiative encourages innovative proposals that explore novel NIBS targets and neurobiological responses, with a focus on understanding the mechanisms underlying SUDs through clinical trials involving human subjects. The NIH plans to allocate $1.5 million annually over three years to fund approximately six grants, with applications due by January 16, 2024. Interested applicants can find more information and guidance on the required Plan for Enhancing Diverse Perspectives (PEDP) at the provided link, and inquiries can be directed to NIH Grants Information at grantsinfo@nih.gov.
    Integrated Functional Mapping and Molecular Profiling of Cell Ensembles Encoding the Effects of Addictive Substances in Rodents (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through its National Institute on Drug Abuse (NIDA), has announced a funding opportunity titled "Integrated Functional Mapping and Molecular Profiling of Cell Ensembles Encoding the Effects of Addictive Substances in Rodents." This initiative aims to support innovative research that utilizes scalable technologies to investigate the cellular responses associated with substance use disorders in rodent models, focusing on integrating neural activity metrics with molecular profiles to enhance understanding of addiction-related neurobehavioral processes. The total funding available is $2 million, with individual grants not exceeding $700,000 in direct costs per year for a project period of up to five years, and proposals must adhere to NIH’s data sharing policies. Interested applicants can find more information and submit inquiries via email to grantsinfo@nih.gov, with the application deadline set for February 23, 2026.
    Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Basic Experimental Studies with Humans (BESH) Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) for exploratory clinical neuroscience research focused on substance use disorders (SUD) through the R61/R33 phased innovation award mechanism. This funding opportunity aims to support clinical research proposals that investigate the neurobiological mechanisms underlying SUD, allowing for up to five years of funding, with the R61 phase dedicated to initial concept testing and the R33 phase contingent upon achieving specific milestones. The initiative is crucial for advancing understanding of substance abuse impacts in the U.S., encouraging innovative research on topics such as neural circuitry and cognitive factors influencing addiction. Interested applicants, including various educational and nonprofit institutions, can find more details and submit applications by the closing date of May 7, 2026, with no cost-sharing requirement. For further inquiries, contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-23-158.html.
    Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Exploratory Clinical Neuroscience Research on Substance Use Disorders" (R61/R33), aimed at supporting innovative clinical research that explores the neurobiological mechanisms underlying substance use disorders (SUD). This initiative encourages applications that investigate neural circuitry and cognitive processes affecting substance use behavior, particularly in the context of the ongoing public health crisis related to SUDs, including the opioid epidemic. The R61/R33 mechanism allows for up to five years of funding, divided into an initial two-year R61 phase and a potential three-year R33 phase, contingent upon meeting specified milestones. Interested applicants can find more information and submit proposals by the application due date of March 13, 2026, and may contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment (R01 Clinical Trial Optional)" aimed at advancing clinical research in the field of substance use disorders (SUD). The primary objective is to identify and validate novel targets for non-invasive brain stimulation (NIBS) and to explore the neurobiological, cognitive, and behavioral responses associated with NIBS that may lead to improved clinical outcomes such as reduced cravings or drug use. This initiative is crucial for enhancing understanding and treatment options for SUD through innovative research methodologies. Funding of up to $1.5 million is available for selected projects over a maximum project period of five years, with applications due by August 14, 2026. Interested applicants can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries and are encouraged to review the detailed application instructions available at the provided link.
    NIDA REI: Research on Neurocognitive Mechanisms Underlying the Impact of Structural Racism on the Substance Use Trajectory (R61/R33 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Drug Abuse (NIDA), is offering a funding opportunity titled "Research on Neurocognitive Mechanisms Underlying the Impact of Structural Racism on the Substance Use Trajectory (R61/R33 Clinical Trial Optional)." This initiative aims to support exploratory and developmental research that investigates how structural racism influences substance use trajectories, with a focus on reducing the risk of substance use disorders and informing preventive strategies. The program encourages a multidisciplinary approach, integrating fields such as neuroscience, epidemiology, and sociology, while promoting community-engaged research methods to enhance racial equity. Interested applicants can apply for funding up to $500,000 for the initial R61 phase, with a total anticipated funding of $1.5 million annually for multiple awards. The application deadline is November 14, 2024, and further details can be found at the provided NIH link or by contacting the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    Functional Validation and/or Characterization of Genes or Variants Implicated in Substance Use Disorders (R21/R33 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Functional Validation and/or Characterization of Genes or Variants Implicated in Substance Use Disorders" (R21/R33), aimed at supporting research projects that explore the genetic underpinnings of substance use disorders. This initiative encourages researchers to utilize innovative methodologies, such as CRISPR technologies, to validate addiction-relevant genes and characterize their roles in living organisms or human organoid systems, thereby enhancing the understanding of neurobiological mechanisms associated with addiction. The funding allows for up to $125,000 per year for the R21 phase over two years and up to $250,000 annually for the R33 phase over three years, with applications due by 5:00 PM local time on February 3, 2025. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov, and additional details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-24-267.html.
    Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Drug Abuse (NIDA), is offering a funding opportunity titled "Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional)" aimed at accelerating the development of medications for Substance Use Disorders (SUDs). This initiative encourages research applications for diverse preclinical and clinical projects that can expedite the FDA approval process for new treatments, addressing the significant public health need for effective therapies for conditions such as cocaine, methamphetamine, and cannabis use disorders. The program will provide cooperative agreements for projects lasting up to three years, with annual budgets capped at $5 million, and applications are accepted on a rolling basis with specific due dates for scientific merit review established throughout 2023 and 2024. Interested applicants can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries, and additional details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-22-202.html.